Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients With Schizophrenia
Michael H. Allen(East Tennessee State University), James V. Cassella(Trevi Therapeutics (United States)), Daniel L. Zimbroff, Daniel A. Spyker(Alexza Pharmaceuticals (United States)), Patrik Munzar, David Feifel(University of California San Diego), Michael D. Lesem(Claghorn Lesem Research Clinic), Ruth Ross
Cited by 99
Related Papers
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
The Psychopharmacology of Agitation: Consensus Statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup
|Western Journal of Emergency Medicine|2012|386
Cerebrospinal Fluid Leptin in Anorexia Nervosa: Correlation with Nutritional Status and Potential Role in Resistance to Weight Gain<sup>1</sup>
|The Journal of Clinical Endocrinology & Metabolism|1997|194
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
|The British Journal of Psychiatry|2011|153
The design and calibration of a startle measurement system
|Physiology & Behavior|1986|142